Published online Jul 15, 2023. doi: 10.4239/wjd.v14.i7.1137
Peer-review started: December 17, 2022
First decision: February 20, 2023
Revised: February 27, 2023
Accepted: June 5, 2023
Article in press: June 5, 2023
Published online: July 15, 2023
Processing time: 204 Days and 17.4 Hours
Maturity-onset diabetes of the young (MODY) is a monogenic genetic disease often clinically misdiagnosed as type 1 or type 2 diabetes. MODY type 9 (MODY9) is a rare subtype caused by mutations in the PAX4 gene. Currently, there are limited reports on PAX4-MODY, and its clinical characteristics and treatments are still unclear. In this report, we described a Chinese patient with high autoimmune antibodies, hyperglycemia and a site mutation in the PAX4 gene.
A 42-year-old obese woman suffered diabetes ketoacidosis after consuming substantial amounts of beverages. She had never had diabetes before, and no one in her family had it. However, her autoantibody tested positive, and she managed her blood glucose within the normal range for 6 mo through lifestyle inter-ventions. Later, her blood glucose gradually increased. Next-generation sequencing and Sanger sequencing were performed on her family. The results revealed that she and her mother had a heterozygous mutation in the PAX4 gene (c.314G>A, p.R105H), but her daughter did not. The patient is currently taking liraglutide (1.8 mg/d), and her blood glucose levels are under control. Previous cases were retrieved from PubMed to investigate the relationship between PAX4 gene mutations and diabetes.
We reported the first case of a PAX4 gene heterozygous mutation site (c.314G>A, p.R105H), which does not appear pathogenic to MODY9 but may facilitate the progression of latent autoimmune diabetes in adults.
Core Tip: Maturity-onset diabetes of the young type 9 (MODY9), as a subtype of MODY caused by mutations in the PAX4 gene, has been poorly reported, and its clinical features and treatments remain unclear. We reported a heterozygous mutation in the PAX4 gene (c.314G>A, p.R105H) in a patient with latent autoimmune diabetes in adults (LADA). Based on the analysis of the cases indexed in PubMed, it is the first reported case of PAX4 with LADA. The PAX4 heterozygous mutation reported in the present case may not be considered for MODY9 and may be facilitated for the onset and progress of LADA.